In this podcast, Dr. Matthew Silva, CEO of Invicro along with Dr. Gregory Goldmacher, Executive Director of Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs discuss innovations in IO imaging.
Together, Dr. Silva and Dr. Goldmacher address:
- The evolution of treatment response criteria in immuno-oncology
- Novel Tracers: Monitoring tumor or immune cell populations with imaging
- Radiomics, AI and Digital Biomarkers
Dr. Silva is CEO of Invicro and leads the strategic vision and mission to support the the drug discovery and development community.
Dr. Silva holds a PhD in Biomedical Engineering from Worcester Polytechnic Institute and brings 17 years of diverse imaging experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the imaging and histopathology groups. Previously, he led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, focusing on the broad use of imaging biomarkers to support drug discovery and development